Post-earnings recap
Reported
Wed, Aug 5, 2026
EPS actual
$0.91
EPS est.
$0.75
EPS surprise
+21.01%
1-day move
+1.25%
Exelixis reported better-than-expected earnings per share, which contributed to a positive stock reaction, with shares rising by 1.25%. However, there was no revenue reported, leaving some uncertainty about overall performance. Investors may be encouraged by the EPS beat but will likely look for more information in future reports.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.91 | $0.86 | +21.01% |
| Revenue | — | $636M | — |
No transcript is on record, and the analysis is based on numerical results only.
Exelixis, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for cancer treatment. Operating in the health care sector, Exelixis plays a crucial role in addressing unmet medical needs in oncology, which is a significant area of investment and research.
Last quarter
In Q1 2026, Exelixis reported an EPS of $0.87, significantly beating expectations of $0.67. This positive surprise of over 29% contributed to a slight increase in stock price the following day.
Management promises and guidance
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+38.72%
Avg 1-day reaction
-0.60%
Analysts are generally optimistic about Exelixis's upcoming earnings, expecting solid performance with an EPS of $0.86 and revenue of $636 million. The company has consistently beaten earnings expectations in the past, which adds to positive sentiment.
Bull case
If Exelixis can maintain its trend of beating earnings expectations, it could see a strong stock price reaction. Additionally, any positive updates on new therapies in development could further boost investor confidence.
Bear case
Conversely, if the company fails to meet the consensus estimates or provides disappointing guidance on future growth, it could lead to a negative reaction in the stock price, especially given the high expectations set by previous quarters.
Key metrics to watch
EPS
0.86Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
636MRevenue figures indicate the company's sales performance and growth potential.
The print will turn on these.
Q1
Will Exelixis achieve an EPS of at least $0.86?
Meeting or exceeding this EPS target is crucial for maintaining investor confidence and could lead to a positive stock reaction.
Q2
What guidance will management provide regarding future revenue growth?
Future revenue guidance will be closely watched as it indicates the company's outlook and growth potential in a competitive market.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±12.7%
Why consensus could be wrong
The Street may underestimate Exelixis's ability to leverage its recent successes in clinical trials, which could lead to stronger-than-expected revenue growth this quarter.
Supporting evidence
The company has consistently beaten EPS estimates, indicating a trend of strong performance.
Options pricing suggests a muted reaction, which may not reflect the potential for a significant upside surprise.
Recent developments in cancer therapies could position Exelixis favorably against competitors.
Key risk
If the company reports an EPS significantly above $0.86, it could challenge the current consensus and lead to a re-evaluation of growth expectations.
Pre-commit to what would confirm each case.
The market is weighing the potential for continued growth against the backdrop of previous strong earnings surprises.
Bull confirmed if
Achieving an EPS of $0.86 or higher with strong revenue growth will confirm the bullish sentiment.
Bear confirmed if
An EPS below $0.77 or disappointing revenue guidance would support the bearish outlook.
What the market is pricing for the move.
Implied Move
±1.04%
Historical Avg
±1.14%
The options market is pricing in a modest move of about 1.04% in either direction following the earnings report, suggesting that investors are anticipating a relatively stable reaction.
Options pricing is in line with the historical average move of 1.14% over the last 8 quarters.
ATM IV
0.4%
30d HV
44.8%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: 13 of 29 (45%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
106.74%
of float
Insider
1.85%
of float
Holders
989
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
29,075,377 sh · $1.7B
11.73%
-5.7%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Exelixis beats expectations and raises guidance, history suggests a potential average one-day move of +2.89%, confirming bullish sentiment.
In line / cautious
If results come in line with expectations, the stock may react cautiously, reflecting uncertainty in future growth prospects.
Miss
A miss on EPS expectations could lead to a decline, with historical patterns suggesting an average one-day move of -0.79%.
The lines on the call that would change the story.
Farallon Capital Management LLC
13,468,010 sh · $787.1M
5.44%
2.7%
Renaissance Technologies, LLC
13,427,993 sh · $784.7M
5.42%
-2.2%
Vanguard Portfolio Management LLC
12,043,122 sh · $703.8M
4.86%
-0.3%
AQR Capital Management, LLC
11,023,943 sh · $644.2M
4.45%
-15.8%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.